|
Volumn 165, Issue 12, 2002, Pages 1579-1580
|
Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: How full is the glass?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT;
GLUCOCORTICOID;
CHRONIC LUNG DISEASE;
CHRONIC OBSTRUCTIVE LUNG DISEASE;
CIGARETTE SMOKING;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
EDITORIAL;
FORCED EXPIRATORY VOLUME;
HEALTH STATUS;
HUMAN;
LUNG FUNCTION;
MAJOR CLINICAL STUDY;
MORTALITY;
PRIORITY JOURNAL;
RISK FACTOR;
STEROID THERAPY;
TREATMENT OUTCOME;
ADMINISTRATION, INHALATION;
ANDROSTADIENES;
ANTI-INFLAMMATORY AGENTS;
FORCED EXPIRATORY VOLUME;
GLUCOCORTICOIDS;
HUMANS;
PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;
TREATMENT OUTCOME;
|
EID: 0037097978
PISSN: 1073449X
EISSN: None
Source Type: Journal
DOI: 10.1164/rccm.2204029 Document Type: Editorial |
Times cited : (17)
|
References (10)
|